<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881190</url>
  </required_header>
  <id_info>
    <org_study_id>C002 CANCER</org_study_id>
    <nct_id>NCT02881190</nct_id>
  </id_info>
  <brief_title>Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered
      intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerance Dose (MTD) of RC48-ADC</measure>
    <time_frame>DLT will be evaluated on Day 28 during cycle 1</time_frame>
    <description>The dose level in which &gt;= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (the drug safety as assessed by NCI-CTCAE v4.0)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The drug safety as assessed by NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <arm_group_label>RC48-ADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form;

          -  Aged 18-75 years;

          -  ECOG physical condition is 0 or 1;

          -  Life expectancy greater than 12 weeks;

          -  Patients with locally advanced or metastatic malignant solid tumors diagnosed by
             pathology and refractory to standard of care therapy, or for whom no standard of care
             therapy is available histology standard of care therapy, or for whom no standard of
             care therapy is available;

          -  Human epidermal growth factor receptor 2 (HER2)-positive refers to
             immunohistochemistry (IHC 2+or 3+);

          -  Patients with measurable and appreciable tumor lesions according to Response
             Evaluation Criteria in Solid Tumors (RECIST 1.1);

          -  Adequate organ function as defined by the following criteria:

               -  absolute neutrophil count(ANC) &gt;= 1.5 x 10(9)/L;

               -  platelets&gt;=70*10(9)/L;

               -  Total serum bilirubin &lt;=1.5*ULN;

               -  serum aspartate transaminase (AST) and serum alanine transaminase (ALT)
                  &lt;=3.0*upper limit of normal (ULN), or AST and ALT&lt;=5*ULN if liver function
                  abnormalities are due to underlying malignancy;

               -  normal serum creatinine;

               -  international normalized ratio(INR) and activated partial thromboplastin time
                  (aPTT) must be less than or equal to 1.5 times the upper limit of the normal
                  range (ULN);

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine
             devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study
             entry and during the period of therapy and for 30 days after the last dose of study
             drug;

          -  Left ventricular ejection fraction (LVEF) &gt;= 50% as assessed by echocardiogram.

        Exclusion Criteria:

          -  Current pregnancy or lactation;

          -  Serologic status reflecting active hepatitis B or C infection;

          -  Major surgery within 4 weeks of first dose of study drug and not fully recovered

          -  Receiving palliative radiation therapy for bone metastases if administered &lt;= 2 weeks
             prior to first study treatment;

          -  Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved
             to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade less than
             or equal to1, or to the levels dictated in the inclusion/exclusion criteria with the
             exception of alopecia;

          -  Prior-treatment with other clinical research anticancer drugs within 28 days before
             study drug treatment;

          -  The active infection with clinical significance According to the researcher's
             judgment,

          -  Known history of immune deficiency,including HIV-positive or other known acquired or
             congenital immunodeficiency, or organ transplantation;

          -  Currently active clinically significant cardiovascular disease such as uncontrolled
             arrhythmia, congestive heart failure, or greater than or equal to Class 2 congestive
             heart failure as defined by the New York Heart Association Functional Classification,
             or history of myocardial infarction unstable angina, or acute coronary syndrome within
             6 months prior to enrollment in the study;

          -  Unwilling or unable to participate in all required study evaluations and procedures;

          -  The time interval which is from the last chemotherapy or HER2 targeted therapy until
             the first trial is more than 21 days;

          -  Patients who had received systemic steroid therapy for a long time (Patients who had
             received systemic steroid therapy for short time and stopped drug more than 2 weeks
             could be enrolled);

          -  Serious complications such as active alimentary tract hemorrhage, intestinal
             obstruction, enteroparalysis, interstitial pneumonia, pulmonary fibrosis, renal
             failure, glaucoma and uncontrolled diabetes;

          -  Uncontrolled primary or metastatic tumor of brain;

          -  Current peripheral neuropathy of Grade ≥ 2;

          -  History of nerve or psychiatric disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Li</last_name>
    <phone>86-010-58075563</phone>
    <email>hnanlilin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

